April 20, 2017April 20, 2017

Boehringer Ingelheim Phase 3 Trial Evaluates Ofev in Patients with Progressive Fibrosing Interstitial Lung Disease

Boehringer Ingelheim Pharmaceuticals has enrolled the first patient in its progressive fibrosing interstitial lung disease (PF-ILD) clinical trial, which will investigate the effectiveness and safety of Ofev (nintedanib) in a ... Read more

March 28, 2017March 28, 2017

Phase 3 Study of Ofev as Treatment for Progressive Fibrosing Lung Diseases Now Enrolling Patients

Idiopathic Pulmonary Fibrosis, News

The first patient has been enrolled in Boehringer Ingelheim’s Phase 3 clinical trial investigating the effectiveness and safety of Ofev (nintedanib) in progressive fibrosing interstitial lung diseases (PF-ILD). ILD encompasses a ... Read more